SURVEY OF THE CHARACTERISTICS OF TACROLIMUS TROUGH CONCENTRATIONS IN KIDNEY TRANSPLANT RECIPIENTS OVER ONE YEAR POST-TRANSPLANT AT MILITARY HOSPITAL 103
Main Article Content
Abstract
Objectives: To investigate the characteristics of tacrolimus (TAC) trough concentrations (C0) and their associations with selected clinical and laboratory parameters in kidney transplant recipients over one year post-transplantation. Methods: A cross-sectional descriptive study was conducted on 532 kidney transplant recipients over one year post-transplant, all receiving an immunosuppressive regimen containing TAC, from January 2024 to September 2024. Data on TAC dosing, C0, and relevant clinical and laboratory parameters were collected for descriptive analysis and association testing. Results: The proportion achieving target TAC C0 levels was 73.68% (392/532 patients), with 1.32% above and 25.00% below the recommended range. Post-transplant duration was significantly associated with abnormal TAC C0 levels (OR = 1.167, p < 0.001). Conclusion: The majority of kidney transplant recipients, over one year post-transplant, achieved TAC C0 within the recommended range. Post-transplant duration was the only factor significantly associated with abnormal C0 levels.
Keywords
Renal transplantation, Tacrolimus, Trough concentrations
Article Details
References
2. Campagne O, Mager DE, Tornatore KM, et al. Population pharmacokinetics of tacrolimus in transplant recipients: What did we learn about sources of interindividual variabilities? The Journal of Clinical Pharmacology. 2019; 59(3):309-325.
3. Hội ghép tạng Việt Nam. Hướng dẫn ghép thận Việt Nam. Nhà xuất bản Y học. Hà Nội. 2017.
4. Ho Trung Hieu, Bui Tien Sy. Risk factors for polyomavirus, cytomegalovirus, and viruria co-infection for follow-up of renal transplant patients. Annals of Transplantation. 2022; 27: e937771.
5. Mager DE, Campagne O, Tornatore KM, et al. Impact of tacrolimus daily dose limitation in renal transplant recipients expressing CYP3A5: A retrospective study. Journal of Personalized Medicine. 2021; 11(11):1002.
6. Kim JH, Han N, et al. Model based development of tacrolimus dosing algorithm considering CYP3A5 genotypes and mycophenolate mofetil drug interaction in stable kidney transplant recipients. Scientific Reports. 2019; 9(1):11740.
7. Han SS, Kim DH, Lee SM, et al. Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants. Kidney Research And Clinical Practice. 2012 Jun 26; 31(3):157-162.
8. Sapir-Pichhadze R, Wang Y, Famure O, Li Y, Kim SJ. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney International. 2014; 85(5):1404-1411.
9. Đàm Thị Thu Hằng và CS. Đánh giá mối liên quan giữa tuân thủ dùng thuốc và biến thiên nồng độ đáy tacrolimus trên bệnh nhân ghép thận tại Bệnh viện Bạch Mai. Tạp chí Y học Việt Nam. 2023.
10. Gandolfini I, Palmisano A, Fiaccadori E, et al. Detecting, preventing and treating non-adherence to immunosuppression after kidney transplantation. Clinical Kidney Journal. 2022 Jan 14; 15(7):1253-1274.